Drug Trial Radar · NCT07247227
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
Last checked: Nov 20, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Oct 10, 2023
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Peking Union Medical CollegeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 25, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This single-arm, multi-center study is to evaluate Sugemalimab plus platinum-based chemotherapy as first-line therapy for patients with locally advanced and metastatic NSCLC in a real-world setting.
Conditions
- NSCLC
Interventions
Sugemalimab and ChemotherapyDrug
Sugemalimab 1200mg plus 4-6 cycles of platinum-based chemotherapy as first-line therapy, followed by Sugemalimab 1200mg to 35 cycles, or until disease progression, or ICF withdrawn by participants, or death or unacceptable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- rw-PFSTime frame: From enrollment to the end of treatment at 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
cancer hospital, Chinese Academy of medical sciences and Peking union medical college
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.